KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) EBT Margin (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of EBT Margin readings, the most recent being 10.97% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 342.0% to 10.97% in Q1 2026 year-over-year; TTM through Mar 2026 was 7.87%, a 1129.0% increase, with the full-year FY2025 number at 7.09%, up 1485.0% from a year prior.
  • EBT Margin hit 10.97% in Q1 2026 for Teva Pharmaceutical Industries, up from 1.7% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 14.42% in Q3 2025 to a low of 31.11% in Q2 2022.
  • Median EBT Margin over the past 5 years was 1.66% (2023), compared with a mean of 4.22%.
  • Biggest five-year swings in EBT Margin: plummeted -3899bps in 2022 and later skyrocketed 4189bps in 2023.
  • Teva Pharmaceutical Industries' EBT Margin stood at 30.51% in 2022, then skyrocketed by 137bps to 11.38% in 2023, then crashed by -175bps to 8.52% in 2024, then skyrocketed by 120bps to 1.7% in 2025, then skyrocketed by 546bps to 10.97% in 2026.
  • The last three reported values for EBT Margin were 10.97% (Q1 2026), 1.7% (Q4 2025), and 14.42% (Q3 2025) per Business Quant data.